TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Most patients with colorectal cancer die as a result of the disease spreading to other organs. However, no prevalent mutations have been associated with metastatic colorectal cancers. Instead, particular features of the tumour microenvironment, such as lack of T-cell infiltration, low type 1 T-helper cell (T H 1) activity and reduced immune cytotoxicity or increased TGFβ levels predict adverse outcomes in patients with colorectal cancer. Here we analyse the interplay between genetic alterations and the tumour microenvironment by crossing mice bearing conditional alleles of four main colorectal cancer mutations in intestinal stem cells. Quadruple-mutant mice developed metastatic intestinal tumours that display key hallmarks of human microsatellite-stable colorectal cancers, including low mutational burden, T-cell exclusion and TGFβ-activated stroma. Inhibition of the PD-1-PD-L1 immune checkpoint provoked a limited response in this model system. By contrast, inhibition of TGFβ unleashed a potent and enduring cytotoxic T-cell response against tumour cells that prevented metastasis. In mice with progressive liver metastatic disease, blockade of TGFβ signalling rendered tumours susceptible to anti-PD-1-PD-L1 therapy. Our data show that increased TGFβ in the tumour microenvironment represents a primary mechanism of immune evasion that promotes T-cell exclusion and blocks acquisition of the T H 1-effector phenotype. Immunotherapies directed against TGFβ signalling may therefore have broad applications in treating patients with advanced colorectal cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Blockade of the TGFβ signaling pathway promotes enough T cell infiltration to make tumors sensitive to PD-1 therapy [39].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [39]
In the citing paper
“Cell analysis of human and mouse CRC specimens showed that CAF is a major contributor to TGF-β production [39].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [39]
In the citing paper
“It has been demonstrated in a variety of tumor models, including CRC models, that activation of CAF may induce PD-1 and CTLA-4 expression on relevant immune cells, which leads to tumor insensitivity to immunotherapy or recurrence [39,304,305,306].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [39]
In the citing paper
“A landmark study from 2018 demonstrated that TGF-β contributes to immune exclusion in colorectal liver metastasis and that inhibition of the TGF-β receptor 1 using the drug galunisertib enhanced tumorous infiltration with T cells, inhibited outgrowth of liver metastases and synergised with anti-PD-L1 therapy to eradicate established lesions.161”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [161]
In the citing paper
“leading to the proposition that combined TGFβ targeting and immune checkpoint blockade may represent an attractive therapeutic strategy for CMS4 colorectal cancer (34).”
From Clinical Challenges of Consensus Molecular Subtype CMS4 Colon Cancer in the Era of Precision Medicine (2024) · cites this paper as [34]
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Fitting Linear Mixed-Effects Models Using lme4
Bates, D., Mächler, M., Bolker, B., & Walker, S. (2015) · Journal of Statistical Software · doi:10.18637/jss.v067.i01 · Cited by 86,835
lmerTest Package: Tests in Linear Mixed Effects Models
Kuznetsova, A., Brockhoff, P. B., & Christensen, R. H. B. (2017) · Journal of Statistical Software · doi:10.18637/jss.v082.i13 · Cited by 24,346
ggplot2: Elegant Graphics for Data Analysis
Wickham, H. (2009) · doi:10.1007/978-0-387-98141-3 · Cited by 14,447
Data Analysis Using Regression and Multilevel/Hierarchical Models
Gelman, A., & Hill, J. (2006) · doi:10.1017/cbo9780511790942 · Cited by 13,597
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Cited by
Items 101–200 of 1,002
Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy
Ciardiello, D., Vitiello, P. P., Cardone, C., Martini, G., Troiani, T., Martinelli, E., & Ciardiello, F. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.04.003 · Cited by 304
Mutational drivers of cancer cell migration and invasion
Novikov, N. M., Zolotaryova, S. Y., Gautreau, A. M., & Denisov, E. V. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01149-0 · Cited by 302
Tharp, K. M., Kersten, K., Maller, O., Timblin, G. A., Stashko, C., Canale, F. P., Menjivar, R. E., Hayward, M.-K., Berestjuk, I., ten Hoeve, J., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00775-4 · Cited by 294
“Our results expand upon the prevailing dogma that cancer fibrosis acts as a physical barrier that causes an ‘immunologically cold’ TME 8,9 .”
Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression
Pu, Y., & Ji, Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.874589 · Cited by 297
“Increased TGF-b levels in the TME not only promoted Tcell exclusion and accumulation of regulatory T cells (Tregs) (33) but also blocked the acquisition of the Th1 effector phenotype (34).”
BackgroundAdaptive Immune Resistance Emerges from Tumor-Initiating Stem Cells
Miao, Y., Yang, H., Levorse, J., Yuan, S., Polak, L., Sribour, M., Singh, B., Rosenblum, M. D., & Fuchs, E. (2019) · Cell · doi:10.1016/j.cell.2019.03.025 · Cited by 299
Colorectal liver metastasis: molecular mechanism and interventional therapy
Zhou, H., Liu, Z., Wang, Y., Wen, X., Amador, E. H., Yuan, L., Ran, X., Xiong, L., Ran, Y., Chen, W., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00922-2 · Cited by 298
“In mice with progressive liver metastatic disease, blockade of TGFβ signaling rendered tumors susceptible to antiprogrammed cell death 1 (PD1) therapy.(169) TGF-β1 could also downregulate the E-cadherin expression and increase the Vimentin expression, inducing EMT to promote the invasion and migration of CRC.”
BackgroundImmunotherapy, Inflammation and Colorectal Cancer
Lichtenstern, C. R., Ngu, R. K., Shalapour, S., & Karin, M. (2020) · Cells · doi:10.3390/cells9030618 · Cited by 294
Lee, J. H., Shklovskaya, E., Lim, S. Y., Carlino, M. S., Menzies, A. M., Stewart, A., Pedersen, B., Irvine, M., Alavi, S., Yang, J. Y. H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15726-7 · Cited by 288
Sun, J.-Y., Zhang, D., Wu, S., Xu, M., Zhou, X., Lu, X.-J., & Ji, J. (2020) · Biomarker Research · doi:10.1186/s40364-020-00212-5 · Cited by 279
Spatial CRISPR genomics identifies regulators of the tumor microenvironment
Dhainaut, M., Rose, S. A., Akturk, G., Wroblewska, A., Nielsen, S. R., Park, E. S., Buckup, M., Roudko, V., Pia, L., Sweeney, R., et al. (2022) · Cell · doi:10.1016/j.cell.2022.02.015 · Cited by 281
Chen, W. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101921-045939 · Cited by 280
“…performed either by specifically inhibiting the expression of perforin, granzymes A and B, Fas ligand, and IFN-γ in a Smad-dependent manner (150) or by indirect suppression through Treg-derived cell membrane–bound TGF-β (151) and via exclusion of CD8 + T cell infiltration to the tumor (152, 153).”
Cancer-Associated Fibroblasts in Inflammation and Antitumor Immunity
Kennel, K. B., Bozlar, M., De Valk, A. F., & Greten, F. R. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1031 · Cited by 279
MDSCs: Key Criminals of Tumor Pre-metastatic Niche Formation
Wang, Y., Ding, Y., Guo, N., & Wang, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00172 · Cited by 281
The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy
Souza-Fonseca-Guimaraes, F., Cursons, J., & Huntington, N. D. (2019) · Trends in Immunology · doi:10.1016/j.it.2018.12.003 · Cited by 279
Systemic inflammation in colorectal cancer: Underlying factors, effects, and prognostic significance
Tuomisto, A. E., Mäkinen, M. J., & Väyrynen, J. P. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i31.4383 · Cited by 271
Clinical development of therapies targeting TGFβ: current knowledge and future perspectives
Ciardiello, D., Elez, E., Tabernero, J., & Seoane, J. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.009 · Cited by 265
Fibroblast heterogeneity in tumor micro-environment: Role in immunosuppression and new therapies
Mhaidly, R., & Mechta-Grigoriou, F. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101417 · Cited by 259
Immunomodulatory TGF-β Signaling in Hepatocellular Carcinoma
Chen, J., Gingold, J. A., & Su, X. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.06.007 · Cited by 260
Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers
Pei, L., Liu, Y., Liu, L., Gao, S., Gao, X., Feng, Y., Sun, Z., Zhang, Y., & Wang, C. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01731-z · Cited by 257
“promote sensitivity to anti-PD-1/PD-L1 immune checkpoint therapy and be particularly useful for treating TGFβ-enriched cancers in the stroma [94].”
BackgroundNeutrophil diversity and function in health and disease
Zhang, F., Xia, Y., Su, J., Quan, F., Zhou, H., Li, Q., Feng, Q., Lin, C., Wang, D., & Jiang, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02049-y · Cited by 246
Cancer-Associated Fibroblasts: Tumorigenicity and Targeting for Cancer Therapy
Glabman, R. A., Choyke, P. L., & Sato, N. (2022) · Cancers · doi:10.3390/cancers14163906 · Cited by 254
Metastatic recurrence in colorectal cancer arises from residual EMP1+ cells
Cañellas-Socias, A., Cortina, C., Hernando-Momblona, X., Palomo-Ponce, S., Mulholland, E. J., Turon, G., Mateo, L., Conti, S., Roman, O., Sevillano, M., et al. (2022) · Nature · doi:10.1038/s41586-022-05402-9 · Cited by 256
Self-citationTumor cell plasticity in targeted therapy-induced resistance: Mechanisms and new strategies
Shi, Z.-D., Pang, K., Wu, Z.-X., Dong, Y., Hao, L., Qin, J.-X., Wang, W., Chen, Z.-S., & Han, C.-H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01383-x · Cited by 256
Host tissue determinants of tumour immunity
Salmon, H., Remark, R., Gnjatic, S., & Merad, M. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0125-9 · Cited by 253
Woolston, A., Khan, K., Spain, G., Barber, L. J., Griffiths, B., Gonzalez-Exposito, R., Hornsteiner, L., Punta, M., Patil, Y., Newey, A., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.013 · Cited by 254
“Our analysis of the immune landscape in CRCs that responded to cetuximab and then progressed shows significantly increased cytotoxic T-cells but also of immune-suppressive cells, such as regulatory T-cells and MDSC.”
BackgroundResultInfluentialThe mesenchymal context in inflammation, immunity and cancer
Koliaraki, V., Prados, A., Armaka, M., & Kollias, G. (2020) · Nature Immunology · doi:10.1038/s41590-020-0741-2 · Cited by 253
Mechanisms of metastatic colorectal cancer
Cañellas-Socias, A., Sancho, E., & Batlle, E. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00934-z · Cited by 249
“Our group used mouse models resembling CAF-rich CMS4 CRCs to demonstrate that elevated TGFβ excluded T cells from liver metastases, whereas pharmacological inhibition of the type I TGFβ receptor enabled T cell infiltration and potent therapeutic effects of anti-PDL1 therapy 47 .”
Self-citationFibroblast pathology in inflammatory diseases
Wei, K., Nguyen, H. N., & Brenner, M. B. (2021) · Journal of Clinical Investigation · doi:10.1172/jci149538 · Cited by 236
“Further, studies of the tumor microenvironment have recently revealed TGF-β ’s critical role in the differentiation of cancer-associated fibroblasts and immune evasion (104, 108, 109).”
BackgroundTransforming Growth Factor-β Signaling in Fibrotic Diseases and Cancer-Associated Fibroblasts
Shi, X., Young, C. D., Zhou, H., & Wang, X.-J. (2020) · Biomolecules · doi:10.3390/biom10121666 · Cited by 243
Fibroblasts in the Tumor Microenvironment: Shield or Spear?
Alkasalias, T., Moyano-Galceran, L., Arsenian-Henriksson, M., & Lehti, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051532 · Cited by 247
“The inhibition of this TGFβ signaling facilitates T cell penetration, thus enhancing anti-PD-L1 therapy response in urothelial and colorectal cancers [152,153].”
BackgroundGoodman, A. M., Piccioni, D., Kato, S., Boichard, A., Wang, H.-Y., Frampton, G., Lippman, S. M., Connelly, C., Fabrizio, D., Miller, V., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1701 · Cited by 247
Lind, H., Gameiro, S. R., Jochems, C., Donahue, R. N., Strauss, J., Gulley, J. L., Palena, C., & Schlom, J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000433 · Cited by 247
Jiménez-Sánchez, A., Cybulska, P., Mager, K. L., Koplev, S., Cast, O., Couturier, D.-L., Memon, D., Selenica, P., Nikolovski, I., Mazaheri, Y., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0630-5 · Cited by 243
Transforming growth factor–β1 in regulatory T cell biology
Moreau, J. M., Velegraki, M., Bolyard, C., Rosenblum, M. D., & Li, Z. (2022) · Science Immunology · doi:10.1126/sciimmunol.abi4613 · Cited by 243
“It is also known that TGF-1–rich stroma reduces the efficacy of immune checkpoint inhibitors (CPIs) due to restrained intratumoral T cell trafficking (154, 155).”
BackgroundThe Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy
Cai, J., Wang, D., Zhang, G., & Guo, X. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s221340 · Cited by 241
“Lately, two studies have confirmed TGF-β secreted by TME is the major driver of immunosuppression leading to the low response to treatment in models of metastatic urothelial and colorectal cancer.(42,64) The increased anti-cancer effect of inhibiting TGF-β or its receptors had been confirmed in some tumor models, but…”
BackgroundTransforming Growth Factor-β Signaling Pathway in Colorectal Cancer and Its Tumor Microenvironment
Itatani, Y., Kawada, K., & Sakai, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235822 · Cited by 240
Precision oncology in metastatic colorectal cancer — from biology to medicine
Di Nicolantonio, F., Vitiello, P. P., Marsoni, S., Siena, S., Tabernero, J., Trusolino, L., Bernards, R., & Bardelli, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00495-z · Cited by 239
Yi, M., Zhang, J., Li, A., Niu, M., Yan, Y., Jiao, Y., Luo, S., Zhou, P., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01045-x · Cited by 233
Wang, Y., Tong, Z., Zhang, W., Zhang, W., Buzdin, A., Mu, X., Yan, Q., Zhao, X., Chang, H.-H., Duhon, M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.683419 · Cited by 224
Han, G., Yang, G., Hao, D., Lu, Y., Thein, K., Simpson, B. S., Chen, J., Sun, R., Alhalabi, O., Wang, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25894-9 · Cited by 225
Chong, W., Shang, L., Liu, J., Fang, Z., Du, F., Wu, H., Liu, Y., Wang, Z., Chen, Y., Jia, S., et al. (2021) · Theranostics · doi:10.7150/thno.52717 · Cited by 229
Pas de Deux: Control of Anti-tumor Immunity by Cancer-Associated Inflammation
Shalapour, S., & Karin, M. (2019) · Immunity · doi:10.1016/j.immuni.2019.06.021 · Cited by 228
“On the other hand, cell death and inflammation induce TGFβ, which promotes CAF activation and fibrosis, resulting in accumulation of a fibrotic tumor stroma that excludes T cells from the tumor and leads to ICI resistance (Mariathasan et al., 2018; Tauriello et al., 2018).”
BackgroundMartin, C. J., Datta, A., Littlefield, C., Kalra, A., Chapron, C., Wawersik, S., Dagbay, K. B., Brueckner, C. T., Nikiforov, A., Danehy, F. T., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay8456 · Cited by 224
TGFβ suppresses CD8+ T cell expression of CXCR3 and tumor trafficking
Gunderson, A. J., Yamazaki, T., McCarty, K., Fox, N., Phillips, M., Alice, A., Blair, T., Whiteford, M., O’Brien, D., Ahmad, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15404-8 · Cited by 220
Haas, L., Elewaut, A., Gerard, C. L., Umkehrer, C., Leiendecker, L., Pedersen, M., Krecioch, I., Hoffmann, D., Novatchkova, M., Kuttke, M., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00221-9 · Cited by 223
Stem-like exhausted and memory CD8+ T cells in cancer
Gebhardt, T., Park, S. L., & Parish, I. A. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00615-0 · Cited by 215
“…promote tumour rejection by mobilizing CD8 + T cells at tumour borders (where cells with a T RM cell phenotype often reside 138 ) to infiltrate the tumour core 195,196 , raising the possibility that such therapies could modulate the anticancer potential of bona fide T RM cells or T RM -like cells.”
BackgroundCancer‐associated fibroblasts: Key players in shaping the tumor immune microenvironment
Desbois, M., & Wang, Y. (2021) · Immunological Reviews · doi:10.1111/imr.12982 · Cited by 216
TGF-β in T Cell Biology: Implications for Cancer Immunotherapy
Dahmani, A., & Delisle, J.-S. (2018) · Cancers · doi:10.3390/cancers10060194 · Cited by 214
Immunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Fu, Q., Xu, L., Wang, Y., Jiang, Q., Liu, Z., Zhang, J., Zhou, Q., Zeng, H., Tong, S., Wang, T., et al. (2019) · European Urology · doi:10.1016/j.eururo.2018.09.030 · Cited by 211
Cancer-associated fibroblasts—heroes or villains?
Gieniec, K. A., Butler, L. M., Worthley, D. L., & Woods, S. L. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0509-3 · Cited by 213
Teixeira, A. F., ten Dijke, P., & Zhu, H.-J. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00605 · Cited by 211
Grauel, A. L., Nguyen, B., Ruddy, D., Laszewski, T., Schwartz, S., Chang, J., Chen, J., Piquet, M., Pelletier, M., Yan, Z., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19920-5 · Cited by 211
TGF-beta: a master immune regulator
Larson, C., Oronsky, B., Carter, C. A., Oronsky, A., Knox, S. J., Sher, D., & Reid, T. R. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1744568 · Cited by 210
“Also in T-cell excluded mouse models, immune checkpoint-resistant microsatellite stable (MSS) colorectal and liver tumors were rendered susceptible to anti-PD-1–PD-L1 therapy with TGF-β blockade [39].”
BackgroundMelisi, D., Oh, D.-Y., Hollebecque, A., Calvo, E., Varghese, A., Borazanci, E., Macarulla, T., Merz, V., Zecchetto, C., Zhao, Y., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002068 · Cited by 206
Desbois, M., Udyavar, A. R., Ryner, L., Kozlowski, C., Guan, Y., Dürrbaum, M., Lu, S., Fortin, J.-P., Koeppen, H., Ziai, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19408-2 · Cited by 208
Cremasco, V., Astarita, J. L., Grauel, A. L., Keerthivasan, S., MacIsaac, K., Woodruff, M. C., Wu, M., Spel, L., Santoro, S., Amoozgar, Z., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0098 · Cited by 207
Chauhan, V. P., Chen, I. X., Tong, R., Ng, M. R., Martin, J. D., Naxerova, K., Wu, M. W., Huang, P., Boucher, Y., Kohane, D. S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819889116 · Cited by 206
“Tumor TGF-β and hypoxia signaling can promote immunosuppression by increasing regulatory T lymphocyte function (15) and by driving exclusion of T lymphocytes from tumors (49, 50).”
BackgroundPaz-Ares, L., Kim, T. M., Vicente, D., Felip, E., Lee, D. H., Lee, K. H., Lin, C.-C., Flor, M. J., Di Nicola, M., Alvarez, R. M., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.03.003 · Cited by 205
TGF-β Signaling in Liver, Pancreas, and Gastrointestinal Diseases and Cancer
Gough, N. R., Xiang, X., & Mishra, L. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.04.064 · Cited by 202
The Role of Tumor Inflammatory Microenvironment in Lung Cancer
Tan, Z., Xue, H., Sun, Y., Zhang, C., Song, Y., & Qi, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.688625 · Cited by 203
Genome-Scale CRISPR Screening in Human Intestinal Organoids Identifies Drivers of TGF-β Resistance
Ringel, T., Frey, N., Ringnalda, F., Janjuha, S., Cherkaoui, S., Butz, S., Srivatsa, S., Pirkl, M., Russo, G., Villiger, L., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.02.007 · Cited by 202
“…of intestinal stem cells (Cammareri et al., 2017; Drost et al., 2015; Fessler et al., 2016), and cell-autonomous inhibition of the pathway enables cancer cells to tolerate elevated TGF-b concentrations in the CRC microenvironment (Muñoz et al., 2006; Takaku et al., 1998; Tauriello et al., 2018).”
BackgroundCancer Vaccines, Adjuvants, and Delivery Systems
Paston, S. J., Brentville, V. A., Symonds, P., & Durrant, L. G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.627932 · Cited by 200
Gunderson, A. J., Rajamanickam, V., Bui, C., Bernard, B., Pucilowska, J., Ballesteros-Merino, C., Schmidt, M., McCarty, K., Philips, M., Piening, B., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1900635 · Cited by 197
Extracellular Matrices and Cancer-Associated Fibroblasts: Targets for Cancer Diagnosis and Therapy?
Belhabib, I., Zaghdoudi, S., Lac, C., Bousquet, C., & Jean, C. (2021) · Cancers · doi:10.3390/cancers13143466 · Cited by 191
“In colorectal cancer, as in metastatic urothelial cancer, the blockade of TGFβ signaling increased tumor sensitivity to anti-PD-L1 by facilitating T lymphocyte infiltration [283,284].”
BackgroundTGF-β Signaling and Resistance to Cancer Therapy
Zhang, M., Zhang, Y. Y., Chen, Y., Wang, J., Wang, Q., & Lu, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.786728 · Cited by 191
“In stratified rectal and genital epithelia lacking type II TGF-β receptor (TβRII) expression, TGF-β signaling is disrupted, leading to destabilized tissue homeostasis and the development of spontaneous SCCs in stratified epithelia (Guasch et al., 2007).”
BackgroundInfluentialNK cells and solid tumors: therapeutic potential and persisting obstacles
Tong, L., Jiménez-Cortegana, C., Tay, A. H. M., Wickström, S., Galluzzi, L., & Lundqvist, A. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01672-z · Cited by 189
“Breast cancer Gastric cancer 1 Recruiting 36 Allogenic Single agent Off-the-shelf product targeting HER2+ tumors NCT04319757 BTC 2–3 Recruiting 128 Allogenic PD-1 blocker Multi-arm study NCT05429697 CRC 1 Not yet recruiting 12 Allogenic IL2 TGFB1 blocker Single-arm study NCT05400122 CRC 1 Recruiting 15 Allogenic Cetux…”
BackgroundInfluentialEvolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression
Wang, R., Song, S., Qin, J., Yoshimura, K., Peng, F., Chu, Y., Li, Y., Fan, Y., Jin, J., Dang, M., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.06.005 · Cited by 187
Tissue-Resident Memory T Cells in Cancer Immunosurveillance
Park, S. L., Gebhardt, T., & Mackay, L. K. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.06.002 · Cited by 193
Panagi, M., Voutouri, C., Mpekris, F., Papageorgis, P., Martin, M. R., Martin, J. D., Demetriou, P., Pierides, C., Polydorou, C., Stylianou, A., et al. (2020) · Theranostics · doi:10.7150/thno.36936 · Cited by 191
TGF-β suppresses type 2 immunity to cancer
Liu, M., Kuo, F., Capistrano, K. J., Kang, D., Nixon, B. G., Shi, W., Chou, C., Do, M. H., Stamatiades, E. G., Gao, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2836-1 · Cited by 187
Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation
Kandalaft, L. E., Dangaj Laniti, D., & Coukos, G. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00503-z · Cited by 180
Bispecific and multispecific antibodies in oncology: opportunities and challenges
Goebeler, M.-E., Stuhler, G., & Bargou, R. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00905-y · Cited by 177
Landscape of Immune Microenvironment Under Immune Cell Infiltration Pattern in Breast Cancer
Xu, Q., Chen, S., Hu, Y., & Huang, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.711433 · Cited by 180
Li, Z., Xu, W., Yang, J., Wang, J., Wang, J., Zhu, G., Li, D., Ding, J., & Sun, T. (2022) · Advanced Materials · doi:10.1002/adma.202200449 · Cited by 178
Therapeutic implications of cancer epithelial-mesenchymal transition (EMT)
Cho, E. S., Kang, H. E., Kim, N. H., & Yook, J. I. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-018-01108-7 · Cited by 180
Dodagatta-Marri, E., Meyer, D. S., Reeves, M. Q., Paniagua, R., To, M. D., Binnewies, M., Broz, M. L., Mori, H., Wu, D., Adoumie, M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0493-9 · Cited by 177
Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01363-8 · Cited by 175
Beyond genetics: driving cancer with the tumour microenvironment behind the wheel
Yuan, S., Almagro, J., & Fuchs, E. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-023-00660-9 · Cited by 169
Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
Shergold, A. L., Millar, R., & Nibbs, R. J. B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104258 · Cited by 174
Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma
Bakouny, Z., Braun, D. A., Shukla, S. A., Pan, W., Gao, X., Hou, Y., Flaifel, A., Tang, S., Bosma-Moody, A., He, M. X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21068-9 · Cited by 174
A single-cell tumor immune atlas for precision oncology
Nieto, P., Elosua-Bayes, M., Trincado, J. L., Marchese, D., Massoni-Badosa, R., Salvany, M., Henriques, A., Nieto, J., Aguilar-Fernández, S., Mereu, E., et al. (2021) · Genome Research · doi:10.1101/gr.273300.120 · Cited by 169
“importantly, as an effective target for therapeutic intervention in oncology (Tumeh et al. 2014; Tauriello et al. 2018).”
BackgroundMethodInfluentialSelf-citationA Perspective on the Development of TGF-β Inhibitors for Cancer Treatment
Huynh, L., Hipolito, C., & ten Dijke, P. (2019) · Biomolecules · doi:10.3390/biom9110743 · Cited by 171
“[62] identified that the activation of TGF-β signaling in the CAFs contributes to T cell exclusion, which results in poor response to immune checkpoint PD-1/PD-L1 blockade mediated by atezolizumab.”
BackgroundOvercoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
Middelburg, J., Kemper, K., Engelberts, P., Labrijn, A. F., Schuurman, J., & van Hall, T. (2021) · Cancers · doi:10.3390/cancers13020287 · Cited by 170
Li, Z., Wang, Y., Shen, Y., Qian, C., Oupicky, D., & Sun, M. (2020) · Science Advances · doi:10.1126/sciadv.aaz9240 · Cited by 171
Wang, H., Li, N., Liu, Q., Guo, J., Pan, Q., Cheng, B., Xu, J., Dong, B., Yang, G., Yang, B., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.05.016 · Cited by 171
Zheng, S., Wang, W., Shen, L., Yao, Y., Xia, W., & Ni, C. (2024) · Experimental Hematology & Oncology · doi:10.1186/s40164-024-00543-1 · Cited by 163
Tumor cell–intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2)
Markosyan, N., Li, J., Sun, Y. H., Richman, L. P., Lin, J. H., Yan, F., Quinones, L., Sela, Y., Yamazoe, T., Gordon, N., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127755 · Cited by 170
“In preclinical studies, we demonstrated the efficacy of a combination therapy, including chemotherapy, agonistic CD40, and ICB, in a genetically engineered mouse model of PDA (23, 24).”
InfluentialImmunomodulation by anticancer cell cycle inhibitors
Petroni, G., Formenti, S. C., Chen-Kiang, S., & Galluzzi, L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0300-y · Cited by 163
The Colorectal Cancer Tumor Microenvironment and Its Impact on Liver and Lung Metastasis
Chandra, R., Karalis, J. D., Liu, C., Murimwa, G. Z., Voth Park, J., Heid, C. A., Reznik, S. I., Huang, E., Minna, J. D., & Brekken, R. A. (2021) · Cancers · doi:10.3390/cancers13246206 · Cited by 167
Yi, M., Wu, Y., Niu, M., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Dai, Z., & Wu, K. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005543 · Cited by 167
Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
Conway, J. R., Kofman, E., Mo, S. S., Elmarakeby, H., & Van Allen, E. (2018) · Genome Medicine · doi:10.1186/s13073-018-0605-7 · Cited by 165
Germann, M., Zangger, N., Sauvain, M., Sempoux, C., Bowler, A. D., Wirapati, P., Kandalaft, L. E., Delorenzi, M., Tejpar, S., Coukos, G., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201910681 · Cited by 164
“MMP9 is known to process latent TGFb into its active form (Yu & Stamenkovic, 2000), and TGFb was recently shown to be part of the immune-suppressive TME in colon tumors (Mariathasan et al, 2018; Tauriello et al, 2018).”
BackgroundTargeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 160
Xie, F., Zhou, X., Su, P., Li, H., Tu, Y., Du, J., Pan, C., Wei, X., Zheng, M., Jin, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31250-2 · Cited by 163
Yi, M., Niu, M., Zhang, J., Li, S., Zhu, S., Yan, Y., Li, N., Zhou, P., Chu, Q., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01155-6 · Cited by 163
CRISPR-Cas-amplified urinary biomarkers for multiplexed and portable cancer diagnostics
Hao, L., Zhao, R. T., Welch, N. L., Tan, E. K. W., Zhong, Q., Harzallah, N. S., Ngambenjawong, C., Ko, H., Fleming, H. E., Sabeti, P. C., et al. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01372-9 · Cited by 163
“We improved their on-target rate with functional biologics that can be extended to scaffolds with therapeutic efficacy, making it possible for combined therapy and diagnostics to monitor treatment responses in real time 51 .”
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Fibroblasts Fuel Immune Escape in the Tumor Microenvironment
De Jaeghere, E. A., Denys, H. G., & De Wever, O. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.09.009 · Cited by 160
Organoid cultures for cancer modeling
Yan, H. H. N., Chan, A. S., Lai, F. P.-L., & Leung, S. Y. (2023) · Cell Stem Cell · doi:10.1016/j.stem.2023.05.012 · Cited by 159
Metadata
- Authors
- Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., Byrom, D., Matarin, J. A., Calon, A., Rivas, E. I., Nebreda, A. R., Riera, A., Attolini, C. S.-O., & Batlle, E.
- Affiliations
- Institute for Research in Biomedicine (ES)
- Universitat Autònoma de Barcelona (ES)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Corresponding author
- Batlle, Eduard
- ORCID
- Venue
- Nature
- Published
- 2018-02
- Volume
- 554
- Issue
- 7693
- Pages
- 538-543
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2788975052
- Cited by
- 1,851
- References
- 43
- Citations by year
- 2026: 193 · 2025: 186 · 2024: 159 · 2023: 211 · 2022: 280 · 2021: 305 · 2020: 247 · 2019: 176 · 2018: 94
- FWCI
- 77.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RECERCAT (Consorci de Serveis Universitaris de Catalunya) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- TGF-beta signaling, colorectal cancer metastasis, immune evasion, T-cell exclusion, tumor microenvironment, immune checkpoint inhibitors, TGF-beta inhibition, liver metastasis, microsatellite stable colorectal cancer, genetically engineered mouse models, organoid transplantation, combination immunotherapy
- MeSH terms
- Alleles, Animals, Cell Differentiation, Colonic Neoplasms, Disease Models, Animal, Drug Synergism, Female, Humans, Immunotherapy, Intestinal Mucosa, Intestines, Liver Neoplasms, Male, Mutation, Neoplasm Metastasis, Stem Cells, T-Lymphocytes, Cytotoxic, Transforming Growth Factor beta, Th1 Cells, Mice, Immune Evasion, Tumor Microenvironment, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.